Spectranetics (SPNC) Announces CE Mark Approval for ThromCatXT
More News related to KNSY
- Kensey Nash (KNSY) Posts Q1 EPS of $0.43; GUides
- Kensey Nash Reports First Quarter Fiscal Year 2010 Financial Results
- Trading Radar for 10/22: AT&T (T), McDonalds (MCD), Amazon.com (AMZN), 3M (MMM), Dow Chemical (DOW), UPS (UPS) Report
- Duncan-Williams Initiates Coverage on Kensey Nash (KNSY) with a Buy; Significant Future Growth in Cardiac Care & Orthopedic Markets
- Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
More News related to SPNC
- Spectranetics to Present at the Canaccord Adams 3rd Annual Cardiovascular Conference on November 10
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Spectranetics (SPNC) Posts Q3 Loss of $0.08
- Spectranetics Reports Third Quarter Revenue Up 7% to $28.8 Million
- Spectranetics to Hold 2009 Third Quarter Financial Results Conference Call on October 28
More News related to FDA
- Canaccord Adams Reiterates a 'Buy' on Veeco Instruments (VECO); Raises PT & Estimates
- Canaccord Adams Reiterates a 'Buy' on NBTY (NTY); Raises PT
- Canaccord Adams Reiterates a 'Buy' on Protalix BioTherapeutics (PLX)
- Canaccord Adams Reiterates a 'Buy' on Rosetta Resources (ROSE); Raises PT
- Wells Fargo Cuts Q4, FY10, FY11 Estimates on Boeing (BA) Following Recent Change to Pension
Spectranetics Corporation (Nasdaq: SPNC) received the CE mark approval for its next-generation ThromCat XT Thrombus Removal System, a single-use, disposable device indicated for mechanical removal of thrombus from native coronary arteries and infra-inguinal arteries.
The launch of the product will commence immediately within the European Union.
The approval triggers a milestone payment of $1.5 million pursuant to the Company's Amended Development and Regulatory Services agreement with Kensey Nash Corporation (Nasdaq: KNSY).
Related Categories
FDAStocks Mentioned
+0.21
-0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
